PMID- 29458962
OWN - NLM
STAT- MEDLINE
DCOM- 20181211
LR  - 20190201
IS  - 2405-8025 (Electronic)
IS  - 2405-8033 (Print)
IS  - 2405-8025 (Linking)
VI  - 4
IP  - 2
DP  - 2018 Feb
TI  - Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment.
PG  - 119-137
LID - S2405-8033(17)30240-6 [pii]
LID - 10.1016/j.trecan.2017.12.007 [doi]
AB  - Dendritic cells (DCs) are essential in immunity owing to their role in activating 
      T cells, thereby promoting antitumor responses. Tumor cells, however, hijack the 
      immune system, causing T cell exhaustion and DC dysfunction. Tumor-induced T cell 
      exhaustion may be reversed through immune checkpoint blockade (ICB); however, 
      this treatment fails to show clinical benefit in many patients. While ICB serves 
      to reverse T cell exhaustion, DCs are still necessary to prime, activate, and 
      direct the T cells to target tumor cells. In this review we provide a brief 
      overview of DC function, describe mechanisms by which DC functions are disrupted 
      by the tumor microenvironment, and highlight recent developments in DC cancer 
      vaccines.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Saxena, Mansi
AU  - Saxena M
AD  - The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York 
      City, NY 10029, USA.
FAU - Bhardwaj, Nina
AU  - Bhardwaj N
AD  - The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York 
      City, NY 10029, USA; Parker Institute of Cancer Immunotherapy, San Francisco, CA 
      94129, USA. Electronic address: nina.bhardwaj@mssm.edu.
LA  - eng
GR  - R01 AI081848/AI/NIAID NIH HHS/United States
GR  - R01 CA180913/CA/NCI NIH HHS/United States
GR  - R01 CA201189/CA/NCI NIH HHS/United States
GR  - T32 AI007605/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Trends Cancer
JT  - Trends in cancer
JID - 101665956
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Animals
MH  - Cancer Vaccines/*therapeutic use
MH  - Dendritic Cells/*immunology
MH  - Humans
MH  - Neoplasms/immunology/*therapy
PMC - PMC5823288
MID - NIHMS937745
OTO - NOTNLM
OT  - cancer
OT  - dendritic cells
OT  - immune suppression
OT  - immunotherapy
OT  - tumor microenvironment
OT  - vaccines
EDAT- 2018/02/21 06:00
MHDA- 2018/12/12 06:00
PMCR- 2019/02/01
CRDT- 2018/02/21 06:00
PHST- 2017/10/16 00:00 [received]
PHST- 2017/12/19 00:00 [revised]
PHST- 2017/12/21 00:00 [accepted]
PHST- 2018/02/21 06:00 [entrez]
PHST- 2018/02/21 06:00 [pubmed]
PHST- 2018/12/12 06:00 [medline]
PHST- 2019/02/01 00:00 [pmc-release]
AID - S2405-8033(17)30240-6 [pii]
AID - 10.1016/j.trecan.2017.12.007 [doi]
PST - ppublish
SO  - Trends Cancer. 2018 Feb;4(2):119-137. doi: 10.1016/j.trecan.2017.12.007.